Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 5/2015

01-05-2015 | Cardiac PET, CT, and MRI (SE Petersen, Section Editor)

Cardiac PET for Translational Imaging

Authors: C. Rischpler, Anna Paschali, Constantinos Anagnostopoulos, S. G. Nekolla

Published in: Current Cardiology Reports | Issue 5/2015

Login to get access

Abstract

All along, translational cardiovascular research has been dependent on non-invasive imaging (such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), echocardiography, or magnetic resonance imaging (MRI)), as these techniques allow the assessment of surrogate markers in intact living organisms non-invasively. PET offers the advantages of high sensitivity; the capability for longitudinal, quantitative imaging; and that an armamentarium of promising radiotracers is readily available. All commercially available PET scanners are equipped with a CT component, and thus, the often cited disadvantage of a lack of morphologic correlation does not really count anymore. This review aims to give an outline on PET as a promising tool for translational research in cardiology as dedicated preclinical systems with virtually the same imaging features as those used in clinical imaging allows the straightforward concept of “bench to bedside.”
Literature
1.•
Chen IY, Wu JC. Cardiovascular molecular imaging: focus on clinical translation. Circulation. 2011;123(4):425–43. Excellent review on a wide range of biological mechanisms and imaging strategies for a wide range of modalities such as PET, SPECT, MRI, and optical imaging.CrossRefPubMedCentralPubMed
2.
Martinez-Moller A, Zikic D, Botnar RM, Bundschuh RA, Howe W, Ziegler SI, et al. Dual cardiac-respiratory gated PET: implementation and results from a feasibility study. Eur J Nucl Med Mol Imaging. 2007;34(9):1447–54.CrossRefPubMed
3.
Phelps ME, Hoffman EJ, Huang SC, Ter-Pogossian MM. Effect of positron range on spatial resolution. J Nucl Med:Off Public Soc Nucl Med. 1975;16(7):649–52.
4.
Cheng AS, Pegg TJ, Karamitsos TD, Searle N, Jerosch-Herold M, Choudhury RP, et al. Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol. 2007;49(25):2440–9.CrossRefPubMed
5.
Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med:Off Public Soc Nucl Med. 2005;46(3):455–63.
6.•
Maddahi J, Packard RR. Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014;44(5):333–43. Overview of established and new flow agents in cardiac PET imaging and their application.CrossRefPubMed
7.
Mc Ardle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60(18):1828–37.CrossRefPubMed
8.•
Yu M, Nekolla SG, Schwaiger M, Robinson SP. The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011;41(4):305–13. Detailed description of the development of a new PET flow tracer from cells over isolated rodents hearts, in vivo rodents and finally into humans.CrossRefPubMed
9.
Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med:Off Public Soc Nucl Med. 2008;49(4):630–6.CrossRef
10.
Higuchi T, Nekolla SG, Huisman MM, Reder S, Poethko T, Yu M, et al. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med:Off Public Soc Nucl Med. 2008;49(10):1715–22.CrossRef
11.
Sherif HM, Saraste A, Weidl E, Weber AW, Higuchi T, Reder S, et al. Evaluation of a novel (18)F-labeled positron-emission tomography perfusion tracer for the assessment of myocardial infarct size in rats. Circ Cardiovasc Imag. 2009;2(2):77–84.CrossRef
12.
Nekolla SG, Reder S, Saraste A, Higuchi T, Dzewas G, Preissel A, et al. Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation. 2009;119(17):2333–42.CrossRefPubMed
13.
Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, et al. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med:Off Public Soc Nucl Med. 2011;52(9):1490–8.CrossRef
14.
Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61(4):469–77.CrossRefPubMedCentralPubMed
15.
Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, et al. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med:Off Public Soc Nucl Med. 2006;47(8):1359–66.
16.
Ilovich O, Abourbeh G, Bocher M, Freedman N, Billauer H, Dotan S, et al. Structure–activity relationship and preclinical evaluation of carbon-11-labeled ammonium salts as PET–myocardial perfusion imaging agents. Molec Imag Biol:MIB: Off Public Acad Molec Imag. 2012;14(5):625–36.CrossRef
17.
Jacobson O, Abourbeh G, Tsvirkun D, Mishani E. Rat imaging and in vivo stability studies using [11C]-dimethyl-diphenyl ammonium, a candidate agent for PET-myocardial perfusion imaging. Nucl Med Biol. 2013;40(8):967–73.CrossRefPubMed
18.
Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010;31(24):2984–95.CrossRefPubMed
19.
Lee WW, Marinelli B, van der Laan AM, Sena BF, Gorbatov R, Leuschner F, et al. PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol. 2012;59(2):153–63.CrossRefPubMedCentralPubMed
20.
Schwaiger M, Hicks R. The clinical role of metabolic imaging of the heart by positron emission tomography. J Nucl Med:Off Public Soc Nucl Med. 1991;32(4):565–78.
21.
Bengel FM, Ueberfuhr P, Ziegler SI, Nekolla SG, Odaka K, Reichart B, et al. Non-invasive assessment of the effect of cardiac sympathetic innervation on metabolism of the human heart. Eur J Nucl Med. 2000;27(11):1650–7.CrossRefPubMed
22.
Fallavollita JA, Heavey BM, Luisi Jr AJ, Michalek SM, Baldwa S, Mashtare Jr TL, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63(2):141–9.CrossRefPubMedCentralPubMed
23.
Nguyen NT, DeGrado TR, Chakraborty P, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-epinephrine in the isolated working rat heart. J Nucl Med:Off Public Soc Nucl Med. 1997;38(5):780–5.
24.
Munch G, Nguyen NT, Nekolla S, Ziegler S, Muzik O, Chakraborty P, et al. Evaluation of sympathetic nerve terminals with [(11)C]epinephrine and [(11)C]hydroxyephedrine and positron emission tomography. Circulation. 2000;101(5):516–23.CrossRefPubMed
25.
Raffel DM, Corbett JR, del Rosario RB, Mukhopadhyay SK, Gildersleeve DL, Rose P, et al. Sensitivity of [11C]phenylephrine kinetics to monoamine oxidase activity in normal human heart. J Nucl Med:Off Public Soc Nucl Med. 1999;40(2):232–8.
26.
Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao PC, Schwaiger M, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med:Off Public Soc Nucl Med. 1996;37(12):1923–31.
27.
Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212–21.CrossRefPubMed
28.
Yu M, Bozek J, Lamoy M, Guaraldi M, Silva P, Kagan M, et al. Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imag. 2011;4(4):435–43.CrossRef
29.
Sinusas AJ, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu YH, et al. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med:Off Public Soc Nucl Med. 2014;55(9):1445–51.CrossRef
30.
Elsinga PH, van Waarde A, Visser TJ, Vaalburg W. Visualization of beta-adrenoceptors using PET. Clin Positron Imag:Off J Inst Clin PET. 1998;1(2):81–94.CrossRef
31.
Le Guludec D, Delforge J, Syrota A, Desruennes M, Valette H, Gandjbakhch I, et al. In vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation. 1994;90(1):172–8.CrossRefPubMed
32.
Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med:Off Public Soc Nucl Med. 2008;49(5):830–6.CrossRef
33.
Lehner S, Todica A, Vanchev Y, Uebleis C, Wang H, Herrler T, et al. In vivo monitoring of parathyroid hormone treatment after myocardial infarction in mice with [68Ga]annexin A5 and [18F]fluorodeoxyglucose positron emission tomography. Mol Imaging. 2014;13:1–8.
Metadata
Title
Cardiac PET for Translational Imaging
Authors
C. Rischpler
Anna Paschali
Constantinos Anagnostopoulos
S. G. Nekolla
Publication date
01-05-2015
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 5/2015
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-015-0581-0

Other articles of this Issue 5/2015

Current Cardiology Reports 5/2015 Go to the issue

Ischemic Heart Disease (D Mukherjee, Section Editor)

Racial Disparities in Outcomes After Cardiac Surgery: the Role of Hospital Quality

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Role for Combination Therapy in Diabetic Dyslipidemia

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Genetic Risk Factors and Mendelian Randomization in Cardiovascular Disease

Interventional Cardiology (S Rao, Section Editor)

Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Statin Intolerance: Diagnosis and Remedies

Ischemic Heart Disease (D Mukherjee, Section Editor)

Cardiovascular, Renal and Overall Health Outcomes After Bariatric Surgery

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits